Drug Trial Radar · NCT04410445
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
Last checked: Nov 19, 2026Latest source record: Apr 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
765
Actual
Start
Jul 27, 2020
Primary completion
Sep 22, 2022
Study completion Sep 22, 2022
Sponsor
- Lead sponsor
- Nektar TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- Jun 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV cutaneous melanoma who are at high risk for recurrence.
Conditions
- Melanoma
- Melanoma Stage III
- Melanoma Stage IV
- Melanoma (Skin)
Interventions
BempegaldesleukinBiological
Specified dose on specified days
NivolumabBiological
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence-free Survival (RFS) by Blinded Independent Central Review (BICR) of Bempegaldesleukin Plus Nivolumab Versus Nivolumab Alone.Time frame: Up to 21 months
Locations
212 sites in 17 countries. Site status is shown where the registry gives one.
Honor Health
Scottsdale, Arizona
Banner MD Anderson Cancer Center
Little Rock, Arkansas
Kaiser Foundation Hospital, Inpatient Pharmacy
Anaheim, California
Kaiser Permanente
Fontana, California
St. Joseph Heritage Healthcare
Fullerton, California
Hematology Oncology Medical Group of Orange County, Inc.
Orange, California
University of California Irvine
Orange, California
Emad Ibrahim, MD, Inc
Redlands, California
Kaiser Permanente
Riverside, California
Southern California Permanente Medical Group
Riverside, California
San Francisco Oncology Associates
San Francisco, California
California Cancer Associates for Research and Excellence
San Marcos, California
Kaiser Permanente
San Marcos, California
Angeles Clinic and Research Institute
Santa Monica, California
John Wayne Cancer Institute
Santa Monica, California
Rocky Mountain Cancer Centers (Littleton) - USOR
Aurora, Colorado
University of Colorado - Cancer Center - PPDS
Aurora, Colorado
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Orlando Health Cancer Institute
Longwood, Florida
Rush University Medical Center
Chicago, Illinois
Goshen Center For Cancer Care
Goshen, Indiana
University of Kentucky
Lexington, Kentucky
Ochsner Clinic Foundation
New Orleans, Louisiana
Massachusetts General Hospital
Boston, Massachusetts
Mayo Clinic - PIN
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Frontier Cancer Center and Blood Institute
Billings, Montana
Nebraska Cancer Specialists
Omaha, Nebraska
Nebraska Methodist Hospital
Omaha, Nebraska
University of Nebraska Medical Center
Omaha, Nebraska
Hackensack University Medical Center
Hackensack, New Jersey
Atlantic Health System
Morristown, New Jersey
NYU Langone Medical Center
New York, New York
Columbia University Medical Center - PIN
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Duke Cancer Institute
Durham, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
The Cleveland Clinic Foundation
Cleveland, Ohio
Providence Cancer Institute, Franz Clinic
Portland, Oregon
Showing 40 of 212 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.